Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring adenocarcinoma of the prostate, stage IV prostate cancer, recurrent prostate cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage IV hormone refractory adenocarcinoma of the prostate Progressive disease despite hormonal therapy or orchiectomy No brain metastases PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil count at least 2,000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 9 g/dL Hepatic: Alkaline phosphatase no greater than 2 times upper limit of normal (ULN) (unless bone metastasis) Bilirubin less than 2 times ULN Renal: Creatinine less than 2 times ULN Cardiovascular: Adequate cardiac function Other: No other prior malignancy except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: See Disease Characteristics Prior corticosteroids allowed if started at least 8 weeks prior to study Radiotherapy: At least 8 weeks since prior extensive radiotherapy Surgery: See Disease Characteristics
Sites / Locations
- Hopital Saint-Louis
- Hopital Gouin
- Hopital Perpetuel Secours
- CHU de la Timone
- Hopital Laennec
- Hopital Saint Antoine
- Hopital Tenon
- Polyclinique De Courlancy
- C.H. Senlis
- Centre Hospitalier Intercommunal Toulon - La Seyne/Mer